Melissa Easy, Founder of DrugDev Selected as a Finalist for IIR Partnerships Woman of the Year
Audubon, PA, February 28, 2014 --(PR.com
)-- IIR’s Partnerships in Clinical Trials named Melissa Easy, founder of DrugDev as a finalist for the IIR Partnerships Woman of the Year Award. The award was created to honor exceptional women in the clinical trials industry who have successfully achieved the highest levels of professional excellence, passionately contributed time and energy to innovative initiatives and actively encouraged and supported others through mentorship and advocacy.
Melissa Easy founded DrugDev in 2009 with a mission to bring Sponsors and Investigators closer together by focusing on the needs of the doctors and has grown the enterprise into the world’s largest Investigator database with over 80,000 actively engaged investigators in 115 countries. With the recent acquisition of CFS Clinical, DrugDev has expanded company capabilities to include site contracting, essential site documents, and Investigator payments continuing the mission of simplifying the clinical trial process by focusing on the Investigator.
“Melissa stayed true to her philosophy of helping Investigators work more effectively with industry - putting the needs and interests of Investigators first - and was rewarded with more active, conversational relationships with Investigators from around the world than most large Sponsors and CROs have built over decades,” states Hugo Stephenson, Executive Chairman of DrugDev. “Melissa is an extraordinary example of achievement in this new phase of our industry and is an amazing role model for her peers.”
Melissa joins industry leaders Patricia Leuchten, CEO, AVOCA Group, Annalisa Jenkins, EVP, Head of Global R&D, Merck Serono and Patricia Devitt Risse, Pharm. D., President and CEO, ACT Oncology as a finalist for the award. The award will be given out at the 3rd Annual Women's Clinical Leadership Forum, on Monday, March 31st as a part of the Partnerships in Clinical Trials conference in Las Vegas, NV.
DrugDev has the industry’s largest global network of active Investigators. At the end of 2013, DrugDev acquired CFS Clinical and together they create global, standardized processes to promote collaboration among Sponsors, CROs and Sites in finding, engaging, and paying Investigators. Innovative solutions include study feasibility, site identification, site contracting, essential document management and Investigator payments. The result — drug developers and Investigators brought closer together with smart technology and unique relationships to help the industry do more trials. www.DrugDev.com or www.CFSClinical.com.